Yifei Wang is the Professor and Vice President of the Institute of Biomedicine of Jinan University; Director of Jinan Biomedical Research and Development Center; Standing director of China institute of biomedical engineering; Chairman of Guangdong institute of biomedical engineering; Vice Chairman of GuangdongBiophysical Society; Executive vice president of Guangdong stem cell and Regenerative Medicine Association. He was awarded the State Council special allowance in 2009, won the national candidate of“Qianbaishi project”in Universities of Guangdong province in 2008, and selected to the national Ministry of personnel of“baiqianwan Talents Project”in 2007. He is mainly engaged in development of medical devices, traditional Chinese medicine and innovative drug discovery, pharmacology research. He has presided and completed the national 12th Five-Year science and technology support program, National 863 plan, National Natural Science Foundation of China, 2011 national major new drug discovery program, National Science and technology innovation fund program for small and medium sized enterprises. He has won three national drug clinical approvals (pharmaceutical raw materials of cepharanthine hydrochloride, cepharanthine hydrochloride injection, Huzhen gout capsule）; three China Patent excellence awards, one Provincial Science and technology progress award; three PCT patents; He has published more than 200 academic papers , including 190 SCI and EI papers. He has four writtings as the main editor.

EDUCATION：

1995.09-1997.07

Post-doctor Major: Clinical Medicine

ZhengzhouUniversity

1992.09-1995.07

Ph.D.Major: Biomedical Engineering

Huazhong University of Science and Technology

1987.09-1989.07

Master Major: Biology

Wuhan Plant Research Institute of CAS

1983.09-1987.07

Bachelor Major: Biology

Henan Normal University

WORK EXPERIENCE：

2004 - present

Professor and Vice President of the Institute of Biomedicine, Jinan University

2006 - present

Director, Biomedical Research and Development Base of Jinan University

2006 - present

Chairman and General Manager, Jinan Biomedical Research and Development Center

2006 - present

Chief Scientist, Guangzhou Selaira Stem Cell Technology Co., Ltd.

2012 - present
Board Member and Chief Scientist, Guangzhou Sande Medical Technology Co., Ltd.

1. - 2006

   Technical Director, Biomedical Research and Development Base of Jinan University

2. - 2000

   Senior Assistant Researcher, Japan National Fusion Technology Research Center

   1997- 1999

   Bioengineering Institute of Jinnan University

   1990– 1992

   Assistant Researcher, Drug Department, Henan Population and Family Planning Science & Technology Research Institute

Development of medical devices, stem cell research, traditional Chinese medicine and innovative drug discovery, pharmacology research：

• Development of medical devices:use advanced research techniques, for example biomedicine, computer science ,to develop new medical devices；

• Stem cell research: isolation and storage of stem cells and its application in medicine；

• Traditional Chinese medicine：extraction and separation of active ingredients and assessment of anti-virus and anti-tumor effectiveness, research and development on innovative Chinese medicine, research and development on healthcare product based on Chinese medicine；

• Innovative drug discovery:  genetic engineering antiviral medicine research, develop broad-spectrum antiviral peptide; marine active ingredients and natural products antivirus, antitumor active ingredients and pharmacological research of innovative drugs.

(1) wu, Huang J, Chu B, et al. Dynamic and Hierarchically-Structured Networks with Tissue-Like Mechanical Behavior[J]. ACS nano, 2019. (Impact Factor:13.6)

(2) Wu C, Wang X, Chu B, et al. Self-Assembly of Core-Corona β-glucan into Stiff and Metalizable Nanostructures from 1D to 3D[J]. ACS nano, 2018(Impact Factor:13.6)

(3) Wu C, Wang X, Wang J, Zhang Z, Wang Z, Wang Y*, Tang S*. Tile-based self-assembly of a triple-helical polysaccharide into cell wall-like mesoporous nanocapsules. Nanoscale. 2017;9:9938-9945.(Impact Factor:7.367)

(4) Jin F, Wang Y, Wang X, Wu Y, Wang X, Liu Q, Zhu Y, Liu E, Fan J, Wang Y*. Bre Enhances Osteoblastic Differentiation by Promoting the Mdm2-Mediated Degradation of p53. Stem Cells. 2017;35:1760-1772.(Impact Factor:5.599)

(5) Zheng K, Jiang Y, Liao C, Hu X, Li Y, Zeng Y, Zhang J, Wu X, Wu H, Liu L, Wang Y*, He Z*. NOX2-Mediated TFEB Activation and Vacuolization Regulate Lysosome-Associated Cell Death Induced by Gypenoside L, a Saponin Isolated from Gynostemma pentaphyllum. J Agric Food Chem. 2017;65:6625-6637.(Impact Factor:3.154)

(6)Wu Y, Jin F, Wang Y, Li F, Wang L, Wang Q, Ren Z, Wang Y*. In vitro and in vivo anti-inflammatory effects of theaflavin-3,3'-digallate on

lipopolysaccharide-induced inflammation. European Journal of Pharmacology. 2017;794:52-60.(Impact Factor:2.896)

(7)Zheng K, Jiang Y, He Z, Kitazato K, Wang Y*. Cellular defence or viral assist: the dilemma of HDAC6. Journal of General Virology. 2017;98:322-337.(Impact Factor:2.838)

(8) Wu, YT  ; Jin, FJ  ; Wang, YL ; Li, F ; Wang, L  ; Wang, QL; Ren, Z ; Wang,YF*. In vitro and in vivo anti-inflammatory effects of theaflavin-3,3 '-digallateon lipopolysaccharide-induced inflammation. EUROPEAN JOURNAL OF

PHARMACOLOGY卷: 794  页: 52-60.DOI: 10.1016/j.ejphar.2016.11.027出版年: JAN 5 2017.(Impact Factor: 2.730)

(9) Wang Y, Jin F, Wang Q, Suo Z. Long-Term Survival of AIDS Patients Treated with Only Traditional Chinese Medicine. AIDS Res Hum Retroviruses. 2017;33:90-92.(Impact Factor:2.095)

(10) Wu Y, Jin F, Wang Y, Li F, Ren Z, Wang Y*. In vitro and in vivo inhibitory effects of 6-hydroxyrubiadin on lipopolysaccharide-induced inflammation.

Immunopharmacol Immunotoxicol. 2017;39:107-116.(Impact Factor:1.475)

(11) Kai Zheng, Yan Li, Shaoxiang Wang, Xiao Wang, Chenghui Liao, XiaopengHu,Long Fan, Qiangrong Kang, Yong Zeng, Xuli Wu, Haiqiang Wu, JianZhang,YifeiWang *&Zhendan He*.Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death viathe CHEK1-mediated DNA Damagecheckpoint.

Autophagy，DOI:10.1080/15548627.2016.1192751.(Impact Factor:9.108)

（12）Kai Zheng, KaioKitazato, Yifei Wang*, and Zhendan He*.Pathogenic microbesmanipulate cofilin activity to subvert actin cytoskeleton.Critical Rev Microbiol，DOI: 10.3109/1040841X.2015.1010139.(Impact Factor:8.192)

（13）Chenghui Liao, Kai Zheng, Yan Li, Hong Xu, Qiangrong Kang, Long Fan, Xiaopeng Hu, Zhe Jin, Yong Zeng, Xiaoli Kong, Jian Zhang, Xuli Wu, Haiqiang Wu, Lizhong Liu, Xiaohua Xiao,Yifei Wang*, Zhendan He* .Gypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca2+ release . Oncotarget, June 18, 2016 .(Impact Factor:5.008)

（14）Liu, Ge; Zhong, Meigong; Guo, Chaowan ; Komatsu, Masaaki ; Xu, Jun ; Wang, Yifei*; Kitazato, Kaio*.Autophagy is involved in regulating influenza A virus RNA and protein synthesis associated with both modulation of Hsp90 induction and mTOR/p70S6K signaling pathway.INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY， 72，100-108，MAR 2016.(Impact Factor: 3.905)

（15）He, Z ; Zhang, L; Zhuo, CQ ; Jin, FJ; Wang, YF*.Apoptosis inhibition effect of Dihydromyricetin against UVA-exposed human keratinocyte cell line. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY卷: 161  页: 40-49 DOI: 10.1016/j.jphotobiol.2016.05.002 出版年: AUG 2016.(Impact Factor: 3.035)

（16）Zheng, Kai ; Liao, Chenghui; Li, Yan; Fan, Xinmin ; Fan, Long ; Xu, Hong ; Kang, Qiangrong ; Zeng, Yong; Wu, Xuli;Wu, Haiqiang ; Liu, Lizhong; Xiao, Xiaohua; Zhang, Jian ; Wang, Yifei* ; He, Zhendan*.Gypenoside L, Isolated from Gynostemmapentaphyllum, Induces Cytoplasmic Vacuolation Death in Hepatocellular Carcinoma Cells through Reactive-Oxygen-Species-Mediated Unfolded Protein Response.JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY，64: 8，1702-1711，MAR 2 2016.(Impact Factor:2.857)

（17）Dong Dong；Xiao Wang；Huailing Wang；Xingwang Zhang；Yifei Wang* ；Baojian Wu*.Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112. International Journal of Nanomedicine，31 march 2015:10，2521-2535.(Impact Factor:4.32)

（18）Wang, Shaoxiang ; Du, Zhan; Luo, Jie; Wang, Xiao; Li, Haiying; Liu, Yuting ; Zhang, Yong ; Ma, Jiwei; Xiao, Weiwei; Wang, Yifei*; Zhong, Xueyun.Inhibition of heat shock protein 90 suppresses squamous carcinogenic progression in a mouse model of esophageal cancer.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY，AUG 2015，141: 8，1405-1416.(Impact Factor: 3.141)

（19）Liu, YT  ; Wang, X  ; Wang, Y ；Zhang, Y ; Zheng, K ; Yan, HZ ；Zhang, L  ; Chen, WB ; Wang, XY  ; Liu,QY ; Wang, SX ; Wang,YF* . Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells. INTERNATIONAL JOURNAL OF ONCOLOGY，46: 1，299-307，JAN 2015.(Impact Factor:3.018)

（20）Wang,X ; Wang, SX ; Liu, YT ; Huang, D ；Zheng, K ;Zhang, Y ; Wang, XY ; Liu, QY ; Yang, DP ;  Wang, YF * .Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells，ONCOLOGY REPORTS，33: 1，230-238，JAN 2015.(Impact Factor:2.486)

（1）Suntor Technology Clinical Skills Training Course,Wang Yifei, Wu Guoxian, First, Jinan University Press, 2018

 (2) Low-frequency electromagnetic bio-conduction technology and pain treatment, Wang Yifei, First Author, Jinan University Press, 2016

（3）Chinese medicine and tumor immune research, Wang Yifei, Lv Yumin, Huang Ziming, First Author, China Medical Science and Technology Society, 1996

（4）Advances in Tumor Immunology, Wang Jianliu, Wang Yifei, Kong Hongxia, Second Author, Henan Medical University Press, 1997

Jan 2019 to Dec 2022

Life Sciences Grant, P.I.( $570000RMB)

Project Title: VP22 or other viral proteins inhibited by TPPP1 and HDAC6 promotes microtubule acetylation and facilitates the mechanism study of HSV-1 intracellular transport

Agency :Project of National Natural Science Foundation(81872908)

Jan 2016 to Dec 2019

Life Sciences Grant, P.I.( $73,529RMB)

Project Title:  Molecular Mechanism of new type Hsp90 inhibitor block HSV-1 assemble and release

Agency :      Project of National Natural Science Foundation（81573471）

Jan 2016 to Dec 2018

Life Sciences Grant, P.I.( $294,117 RMB)

Project Title:   Class I new drug Preclinical researches of AT533 anti typeⅠherpes simplex virus

Agency :      Guangzhou Collaborative innovation major projects of industry, education, and research（201504291048224）

Apr. 2016 to Mar. 2018

Life Sciences Grant, P.I.( $73,529RMB)

Project Title:    Molecular Mechanism of new type Hsp90 inhibitor block HSV-1

Agency :       International cooperation project of Guangdong（2015A050502028）

Jan 2014 to Dec 2016

Life Sciences Grant, P.I.( $161,764 RMB)

Project Title:    An annual output of 100 tons of seaweed sulfated polysaccharides and series product development

Agency :       Special projects of Guangdong marine strategic emerging industries（GD2013-B02-003）

Jan 2013 to Dec 2016

Life Sciences Grant, P.I.( $102,941 RMB)

Project Title:    Mechanism of active ingredients of Phyllanthus emblica L. PGG anti-herpes simplex virus

Agency :       Project supported by National Natural Science Foundation of China(81274170)

Jun. 2013 to Jun. 2016

Life Sciences Grant, P.I.( $447,058 RMB)

Project Title:    Integrated platform and Application of Industrial microbial technology in Pan Pearl River area（High throughput screening technology laboratory of functional active strains and compounds）

Agency :      Marine economic innovation and development regional demonstration project of Guangdong Marine Fishery Bureau（GD2012-D01-002）

Jan 2012 to Dec 2015

Life Sciences Grant, P.I.( $70,588 RMB)

Project Title:   Discovery and drug development anti-herpes simplex virus drug,based on the small molecular compound

Agency :       National Science and technology support program of 12^th

Five-Year（SQ2011SF12B02099）

Jan 2011 to Dec 2013

Life Sciences Grant, P.I.( $136,764RMB)

Project Title:    Huzhen gout capsule

Agency :      2011 national major new drug discovery program（2011ZX09401-307）

Jan 2007 to Dec 2010

Life Sciences Grant, P.I.( $ 161,764RMB)

Project Title:   Study on the antiviral activity composition of the South medicine

Agency :      Guangdong joint fund of National Natural Science Foundation of China（U0632010）

Jun.2007 to Nov.2010

Life Sciences Grant, P.I.( $ 423,529RMB)

Project Title:   Clinical study of small molecule targeted inhibitors and anticancer drugs of heat shock protein（Hsp90）

Agency :       National 863 and 11th Five-Year project（2007AA02Z142）

September18, 2015  Patent(PCT/CN2011/071022, No.5809702):Preparation method and application of Hsp90 inhibitor Xbj-B16-1

May 26, 2010       Patent(ZL200610037537.0):Medicine for treating gouty arthritis and its processing method and Application

May 26, 2010       Patent(ZL200710064821.1):Aplication ofFour hydrogen ketone ketone/ Four hydrogen indazolone /Four hydrogen carbazole derivatives and their salts in the preparation of antiviral drugs

July 22, 2011       Patent（ZL200810055738.2):Indazole derivatives and salts of four hydrogen indazolone or four hydrogen substituted indole ketone

February 22, 2012   Patent（ZL201010614697.3):Application of human stem cell growth factor in cosmetics

August 27,2014     Patent（ZL201110449577.7):Preparation method and application of human stem cell growth factor liposome

July 04, 2012       Patent(ZL201010299615.0):Preparation method and application of Hsp90 inhibitor Xbj-B16-1

July 23,2014        Patent(ZL201310059961.5):Method for detecting Huzhen gout capsule 

May 06,2016        Patent(ZL201410114414.7):Medicinal hard capsule shell material containing Eucheuma gelatinae polysaccharide and its preparation method

November 02,2016   Patent(ZL201510051928.7):A 2- (-3- amino alkyl granatum) benzamide compounds -4- four hydrogen substituted indazole and its application

August 05,2016     Patent(201410424318.2):Nano suspension agent of Hsp90 inhibitor with benzamide as basic framework and preparation method

Genetic engineering

National Engineering Research Center for genetic engineering drugs, Vice director

Guangdong Biomedical Engineering Society, Chairman

Biophysical Society of Guangdong,Vice Chairman

Association of Biomedical Engineering, Standing director

Guangdong stem cell and Regenerative Medicine Association, Executive vice president

《Medical Labaratory Technology》,The editorial board of the Journal